Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:CORT News 16 December 2025 - 2 January 2026

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept shares closed down 50.4% at $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing insufficient evidence. Truist cut its price target to $50 and Wolfe downgraded the stock to Underperform with a $30 target. The FDA set a July 11, 2026 decision date for relacorilant in ovarian cancer. U.S. markets are closed Thursday for New Year’s Day.
1 January 2026
··
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics shares fell 50.4% to $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing a need for more evidence of effectiveness. The company plans to meet with the agency to discuss next steps. Wolfe Research downgraded the stock and removed projected sales for the indication. Trading volume reached about 20.16 million shares.
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept shares plunged about 50% in after-hours trading after the FDA declined to approve relacorilant for hypertension linked to hypercortisolism. The agency requested more evidence of effectiveness, despite acknowledging trial data. Wolfe Research downgraded the stock and slashed its price target. Corcept said it plans to meet with the FDA to discuss next steps.
1 January 2026
··
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept shares plunged nearly 50% to $35.31 after the FDA rejected relacorilant for Cushing’s-related hypertension, citing insufficient evidence of effectiveness. The move erased about $3.7 billion in market value. Corcept said it will meet with the FDA to discuss next steps. The company is also awaiting a July 2026 FDA decision on relacorilant in ovarian cancer.
31 December 2025
··
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics shares fell 8.9% to $72.72 in early afternoon trading Tuesday as investors awaited the FDA’s decision on relacorilant, due later in the day. SEC filings showed CEO Joseph Belanoff and Chief Business Officer Gary Charles Robb exercised stock options and withheld shares for taxes. About 897,000 shares changed hands. The drop outpaced declines in major biotech indexes.
30 December 2025
··
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics shares fell 9% to $79.44 on December 16, 2025, after UBS initiated coverage at Neutral with a $95 target, citing valuation concerns. The stock had surged about 75% year-to-date. No major clinical or regulatory news drove the drop. Trading volume reached approximately 1.27 million shares.
16 December 2025
···

Stock Market Today

Keppel stock price in focus as broker lifts target and dividend clock ticks

Keppel stock price in focus as broker lifts target and dividend clock ticks

8 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, outperforming the Straits Times Index. UOB Kay Hian raised its target price to S$13.23 after Keppel announced a 38% higher FY2025 dividend, with key dates set for April. The M1 sale remains delayed pending regulatory approval. Investors await updates on asset sales and dividend plans when trading resumes Monday.
DBS share price: DBS Group Holdings stock in focus before Feb 9 earnings

DBS share price: DBS Group Holdings stock in focus before Feb 9 earnings

8 February 2026
DBS closed at S$59.30 on Friday, down 0.6%, ahead of its full-year results due before market open on Feb. 9. Singapore shares fell 0.8% the same day as regional markets slid. Investors await updates on DBS’s margins and capital return plan. Singapore’s Budget 2026 is set for Feb. 12, with UOB and OCBC results later this month.
Go toTop